Depo-Provera lawsuit claims allege that long-term use of the injectable contraceptive caused meningioma, a type of brain tumor. Federal cases are centralized in MDL 3140 in the Northern District of Florida, which listed 6,412 pending actions on October 1, 2026. The parties signed a Master Settlement Agreement on July 21, 2026, and settlement registration closes November 30, 2026.

Edited by: Mason ArnaoUpdated: Purpose: educational information, not legal advice

Updates on Depo-Provera Lawsuit

Key facts (as of October 2026)

  • Feb. 7, 2025: The JPML centralized federal cases in MDL 3140 before Judge M. Casey Rodgers (N.D. Fla.).
  • Dec. 12, 2025: The FDA approved labeling that adds meningioma risk to the Warnings and Precautions section for Depo-Provera CI and Depo-SubQ Provera 104.
  • July 21, 2026: The parties signed a Master Settlement Agreement; they estimate roughly 80% of MDL plaintiffs will be eligible.
  • Aug. 5, 2026: BrownGreer PLC was appointed Settlement Administrator.
  • Oct. 1, 2026: 6,412 actions were pending in MDL 3140, out of 6,524 filed.
  • Nov. 30, 2026: Deadline for claimants to register for the Settlement Program.

What the Depo-Provera lawsuits claim

The lawsuits allege that Depo-Provera and its generic equivalents, injectable forms of medroxyprogesterone acetate (MPA), can cause meningiomas, and that the manufacturers knew of the risk and failed to warn. Plaintiffs also question whether defendants failed to promote a safer alternative, Depo-SubQ Provera 104; defendants maintain the drug is safe and effective. Much of the science traces to a French case-control study in The BMJ (March 27, 2024) comparing 18,061 women who had meningioma surgery with 90,305 controls, which reported an odds ratio of 5.62 for MPA use of a year or more. An observational association does not prove what caused any individual tumor.

Where the litigation stands

Under Case Management Order No. 12 (July 27, 2026), the agreement announced June 15, 2026 and signed July 21, 2026 resolves a majority of claims in the MDL and in New York state court, and payments are expected to begin by the first quarter of 2027. Orders entered September 4, 2026 appointed a qualified settlement fund administrator, a lien resolution master and a supplemental compensation fund allocation master. No fund size or per-claimant amounts have been made public. CMO 14 (August 10, 2026) stayed most MDL proceedings while the program is implemented and reported that the preemption motion had been argued and general-causation briefing was complete. The court's next case management conference is set for December 18, 2026.

Who may qualify

The full eligibility criteria sit in the Master Settlement Agreement, which has not been published. Court orders identify two groups that are not eligible: "Limitations Plaintiffs," because of when they filed suit, and "Latency Plaintiffs," because of when their meningioma was diagnosed relative to their last MPA use. In general, a claim may depend on a confirmed meningioma diagnosis, records showing Depo-Provera or generic MPA injections, and the time between use and diagnosis.

Deadlines and next steps

CMO 14 sets November 30, 2026 as the registration deadline for the Settlement Program. Statutes of limitations for new lawsuits vary by state and often run from when an injury was, or should have been, discovered. CMO 14 also requires newly filed plaintiffs alleging a meningioma that developed before March 27, 2024 to file a certification addressing the statute of limitations. Our state-by-state deadline guide and Depo-Provera claim calculator explain the factors involved.

Frequently asked questions

Is there a Depo-Provera settlement?

Yes. The parties signed a Master Settlement Agreement on July 21, 2026, after announcing a global agreement on June 15, 2026. According to Case Management Order No. 12, it covers a majority of claims in MDL 3140 and New York state court, roughly 80% of MDL plaintiffs are expected to be eligible, and payments are expected to begin by the first quarter of 2027.

How much is a Depo-Provera settlement worth per person?

No official figure exists. Neither the court nor the parties have published a fund size, a payout matrix or per-claimant ranges, so any specific dollar estimate circulating online is not drawn from the court record. Individual awards will depend on criteria in the unpublished agreement, which BrownGreer PLC administers as Settlement Administrator under CMO 13.

What is the deadline to register?

Case Management Order No. 14, entered August 10, 2026, sets November 30, 2026 as the deadline for claimants to register for the Settlement Program. Claimants the Settlement Administrator finds ineligible will then be identified to the court. Registration is separate from a state statute of limitations, which still governs whether a new lawsuit can be filed.

What happens to cases that are not eligible?

They continue in litigation. CMO 12 says the court will rule on preemption and general causation for ineligible and opt-out cases. CMO 14 requires litigating plaintiffs to send preservation notices within 60 days, and complete document production and expert reports within 90 days, of their trigger event.

Sources

Related on TortAdvisor: Depo-Provera lawsuit guide · Depo-Provera settlement amounts · Depo-Provera calculator · What the global agreement means · Deadlines by state

Filter Posts

Browse by Category